While STE treatment influenced OVA-specific IgE levels, only the STE200-treated and Dex-treated groups demonstrated component-dependent decreased levels of OVA-specific IgE compared with the OVA-induced asthma group (Figure 7C), although there was no significant difference. This evidence concerns the gene IGHE and asthma.